2021

Celularity and MaxCyte Sign Strategic Platform License to Advance Celularity’s Off-the-shelf Allogeneic Cellular Therapy Product Candidates

May 25, 2021
Read Full Release

Proposed Dual-Listing on Nasdaq

May 14, 2021
Read Full Release

MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences

February 23, 2021
Read Full Release

Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs

January 11, 2021
Read Full Release

2020

CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting

November 9, 2020
Read Full Release

MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences

November 9, 2020
Read Full Release

MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments

October 13, 2020
Read Full Release

MaxCyte to Present at Upcoming 2020 H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference

September 10, 2020
Read Full Release

MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer

September 9, 2020
Read Full Release

CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11

August 18, 2020
Read Full Release

APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401

July 8, 2020
Read Full Release

MaxCyte’s CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York

February 5, 2020
Read Full Release

2019

MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update

December 19, 2019
Read Full Release

MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs

December 4, 2019
Read Full Release

Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer

November 21, 2019
Read Full Release

MaxCyte to Present at BIO-Europe 2019

November 6, 2019
Read Full Release

MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients

October 24, 2019
Read Full Release

MaxCyte Announces Presentations at 5th Annual Cell & Gene Therapy Congress Highlighting Unique Promise of Its Technology

October 23, 2019
Read Full Release

MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum

October 15, 2019
Read Full Release

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

October 7, 2019
Read Full Release

MaxCyte to Present Updates on ExPERT™ Platform at Upcoming Conferences

October 2, 2019
Read Full Release

MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings

September 30, 2019
Read Full Release

MaxCyte Announces Presentation at ICLE 2019

September 9, 2019
Read Full Release

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

July 23, 2019
Read Full Release

MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention

May 29, 2019
Read Full Release

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

May 8, 2019
Read Full Release

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

May 1, 2019
Read Full Release

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

April 8, 2019
Read Full Release

New Processing Assemblies Deliver Increased Flexibility, Efficiency, and Ease of Cell Recovery

March 29, 2019
Read Full Release

NK Cells: The Latest Recruits in the Battle Against Cancer

March 29, 2019
Read Full Release

Don’t Settle for Just Your Average CHO and Other Cell Line Development Advances

March 29, 2019
Read Full Release

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe

March 18, 2019
Read Full Release

2018

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019

December 19, 2018
Read Full Release

MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference

November 21, 2018
Read Full Release

Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

November 14, 2018
Read Full Release

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

November 9, 2018
Read Full Release

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®

October 30, 2018
Read Full Release

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

October 10, 2018
Read Full Release

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences

August 29, 2018
Read Full Release

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

July 16, 2018
Read Full Release

MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease

June 11, 2018
Read Full Release

MaxCyte, Inc. to Present at 2018 BIO International Convention

May 29, 2018
Read Full Release

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)

May 21, 2018
Read Full Release

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)

May 21, 2018
Read Full Release

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer

April 25, 2018
Read Full Release

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month

March 12, 2018
Read Full Release

Dr. Richard Douglas Joins MaxCyte Board

February 13, 2018
Read Full Release

MaxCyte, Inc. to Present at Two Life Sciences Conferences

January 2, 2018
Read Full Release

2017

MaxCyte, Inc. to Present at Phacilitate’s Cell & Gene Therapy Europe Conference

September 14, 2017
Read Full Release

MaxCyte Appoints Executive Vice President of Global Marketing

August 14, 2017
Read Full Release

MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy

June 7, 2017
Read Full Release

MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease

April 25, 2017
Read Full Release

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with Maxcyte

March 14, 2017
Read Full Release

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting

March 2, 2017
Read Full Release

MaxCyte, Inc. to Present at Phacilitate Cell & Gene Therapy World Conference

January 16, 2017
Read Full Release

MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene

January 12, 2017
Read Full Release

2016

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies

December 21, 2016
Read Full Release

MaxCyte Appoints Executive Vice President, Business and Strategic Development

November 2, 2016
Read Full Release

MaxCyte, Inc. to Present at 2016 Cell & Gene Meeting on the Mesa and Biotech Week Boston 2016

September 29, 2016
Read Full Release

MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems

September 6, 2016
Read Full Release

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up